Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | MAOA | P21397 | 1/20 | 0.69 |
| ▸ | RAB9A | P51151 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | LTA4H | P09960 | 1/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4449735 | 0.98 | MAOB (0.73) | MAOBGAAMAPTMAOARAB9A | |
| SCHEMBL20249529 | 0.91 | FFAR1 (0.65) | MAOBGAAMAPTMAOARAB9A | |
| SCHEMBL3172626 | 0.89 | LTA4H (0.70) | MAOBGAAMAPTMAOARAB9A | |
| SCHEMBL7281616 | 0.87 | LTA4H (0.68) | MAOBGAAMAPTMAOARAB9A | |
| SCHEMBL28428692 | 0.85 | MAOB (0.65) | MAOBGAAMAPTMAOARAB9A | |
| SCHEMBL13886600 | 0.85 | NPC1 (0.76) | RAB9ASMN1; SMN2LTA4H | |
| SCHEMBL119690 | 0.84 | MAOB (0.96) | MAOBGAAMAPTMAOARAB9A | |
| SCHEMBL10609652 | 0.83 | LMNA (0.75) | MAOBGAAMAPTMAOARAB9A | |
| SCHEMBL339813 | 0.83 | LMNA (0.82) | MAOBGAAMAPTMAOARAB9A | |
| SCHEMBL27367676 | 0.83 | LMNA (0.82) | MAOBGAAMAPTMAOARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4857522-A | Derivatives of pravastatin for inhibiting cholesterol biosynthesis | E. R. SQUIBB & SONS, INC. (US) | 1989-08-15 | — | — | US | claimed |
| WO-2023213728-A1 | SUBSTITUTED ARYL ESTERS OF COUMARIN-3-CARBOXYLIC ACID AND THEIR USE AS HOST CELL PROTEASES INHIBITORS | Université de Liège (BE) | 2023-11-09 | — | — | WO | disclosed |
| US-11685725-B2 | YAP1 inhibitors that target the interaction of YAP1 with OCT4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11530220-B2 | Substituted imidazo[1,5-a]pyrazines and [1,2,4]triazolo[4,3-a]pyrazines for the modulation of AhR | IDEAYA BIOSCIENCES, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11530220-B2 | Substituted imidazo[1,5-a]pyrazines and [1,2,4]triazolo[4,3-a]pyrazines for the modulation of AhR | IDEAYA BIOSCIENCES, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-20210079001-A1 | COMPOUNDS AND METHODS FOR THE MODULATION OF AHR | IDEAYA BIOSCIENCES, INC. | 2021-03-18 | — | — | US | disclosed |
| WO-2020252222-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2020-12-17 | — | — | WO | disclosed |
| EP-3670511-A1 | TETRAHYDROPROTOBERBERINE COMPOUND, PREPARATION METHOD THEREFOR AND USES THEREOF, AND PHARMACEUTICAL COMPOSITION | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019156989-A1 | COMPOUNDS AND METHODS FOR THE MODULATION OF AhR | IDEAYA BIOSCIENCES, INC. (US) | 2019-08-15 | — | — | WO | disclosed |
| WO-2019156989-A1 | COMPOUNDS AND METHODS FOR THE MODULATION OF AhR | IDEAYA BIOSCIENCES, INC. (US) | 2019-08-15 | — | — | WO | disclosed |
| WO-1994020491-A1 | BENZOPYRANES AS POTASSIUM CHANNEL OPENERS | PFIZER LIMITED (GB) | 1994-09-15 | — | — | WO | disclosed |
| US-5155229-A | Inhibit cholesterol biosynthesis, radioimmunoassay of pravastatin and its derivatives | E. R. SQUIBB & SONS, INC. (US) | 1992-10-13 | — | — | US | disclosed |
| US-5155229-A | Inhibit cholesterol biosynthesis, radioimmunoassay of pravastatin and its derivatives | E. R. SQUIBB & SONS, INC. (US) | 1992-10-13 | — | — | US | disclosed |
| US-5047549-A | Radioimmunoassay | E. R. SQUIBB & SONS, INC. (US) | 1991-09-10 | — | — | US | disclosed |
| US-5047549-A | Radioimmunoassay | E. R. SQUIBB & SONS, INC. (US) | 1991-09-10 | — | — | US | disclosed |
| US-4868296-A | 6-(1-carbamoyl-1-hydroxymethyl) penicillanic acid derivatives | PFIZER INC. (US) | 1989-09-19 | — | — | US | disclosed |
| US-4857522-A | Derivatives of pravastatin for inhibiting cholesterol biosynthesis | E. R. SQUIBB & SONS, INC. (US) | 1989-08-15 | — | — | US | disclosed |
| US-4857522-A | Derivatives of pravastatin for inhibiting cholesterol biosynthesis | E. R. SQUIBB & SONS, INC. (US) | 1989-08-15 | — | — | US | disclosed |
| US-4797394-A | 6-(1-carbamoyl-1-hydroxymethyl)penicillanic acid derivatives | PFIZER INC. (US) | 1989-01-10 | — | — | US | disclosed |
| EP-0220939-A1 | 6-(1-Carbamoyl-1-hydroxymethyl)penicillanic-acid derivatives | PFIZER INC. (US) | 1987-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685725-B2 | YAP1 inhibitors that target the interaction of YAP1 with OCT4 | YAP1, YES1, MYC | MAOB 4496/4885GAA 4876/4885MAPT 4012/4885 |
| US-20210079001-A1 | COMPOUNDS AND METHODS FOR THE MODULATION OF AHR | AHR, ARNT, MTNR1A | MAOB 276/4885GAA 3790/4885MAPT 4286/4885 |
| US-11530220-B2 | Substituted imidazo[1,5-a]pyrazines and [1,2,4]triazolo[4,3-a]pyrazines for the modulation of AhR | AHR, ARNT, CYP1A1 | MAOB 576/4885GAA 4567/4885MAPT 4286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.